Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 12/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5545532 | 0.84 | PYGM (1.00) | PYGMTP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL5550461 | 0.83 | PYGM (0.71) | PYGMTP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL6371489 | 0.82 | PYGM (1.00) | PYGMTP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL5545726 | 0.79 | PYGM (0.72) | PYGMMAPT | |
| SCHEMBL6372041 | 0.79 | PYGM (1.00) | PYGMTP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL6369652 | 0.79 | PYGM (0.66) | PYGMTP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL6371208 | 0.78 | PYGM (0.65) | PYGMTP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL5545650 | 0.77 | PYGM (0.66) | PYGMTP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL5547089 | 0.77 | PYGM (0.69) | PYGMTP53MAPTRXFP1SMN1; SMN2 | |
| SCHEMBL5545707 | 0.76 | PYGM (0.71) | PYGMTP53MAPTRXFP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148586-A1 | Quinoxalinones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-07 | — | — | US | claimed |
| EP-1711184-B1 | (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-18 | — | — | EP | disclosed |
| US-20050148586-A1 | Quinoxalinones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148586-A1 | Quinoxalinones | SLC5A2, GPR119, GLS2 | PYGM 271/4885TP53 3080/4885MAPT 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.